34. Reminds the Commission to pay particular attention to the ‘non-tariff barriers’ and regulatory barriers used by many countries, including WTO members, vis-à-vis EU exports, not least with a view to future trade partnership agreements; points out that, during negotiations, provision should be made for intervention instruments aimed at restoring reciprocity and conditions of equilibrium between the parties in the event of unilateral measures (‘non-tariff barriers’) being taken, including merely administrative measures (certification, inspection), which may place EU businesses at a competitive disadvantage and give rise to asymmetrical operating condition ...[+++]s; calls on the EU to take steps at international level in favour of regulatory cooperation with a view to promoting equivalence and convergence of international standards and thereby limiting disputes and the associated trade costs;

I do not want to see origin marking as a non-trade barrier.

In the Commission's view, is it consistent with the provisions of the Treaty on the free movement of goods and with Court of Justice case law concerning parallel imports of pharmaceuticals for national courts to justify their ruling that the above practice is illegal on the grounds, for example, that the lack of access to the market is solely a commercial obstacle which importers must seek to overcome by means of (in principle unrestricted) marketing which targets prescribing doctors (despite the fact that parallel importers do not have access to Drug Master Files or equivalent scientific/technical data, and regardless of whether the pri ...[+++]ce of the pharmaceutical is regulated by rules on the dispensing of medicines)?

In the Commission's view, is it consistent with the provisions of the Treaty on the free movement of goods and with Court of Justice case law concerning parallel imports of pharmaceuticals for national courts to justify their ruling that the above practice is illegal on the grounds, for example, that the lack of access to the market is solely a commercial obstacle which importers must seek to overcome by means of (in principle unrestricted) marketing which targets prescribing doctors (despite the fact that parallel importers do not have access to Drug Master Files or equivalent scientific/technical data, and regardless of whether the pri ...[+++]ce of the pharmaceutical is regulated by rules on the dispensing of medicines)?

For this, it proposes three categories of action: promoting intelligent vehicle safety systems, adapting the regulatory and standardisation provisions, and removing the societal and business obstacles.

To promote the large-scale marketing of intelligent car safety systems, it proposes three types of actions: promoting intelligent safety systems, adapting legislation and standards, and removing social and commercial barriers.